Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Sciendo
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/68c13731127941479f89d5929d224e01 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|